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The Frequency of Genetic Polymorphisms of CYP2C19 in Native Hawaiian, and Asian 
and Pacific Islander Subgroups: Implications for Personalized Medicine
Khalifa Alrajeh, PharmD, MSCR, Ph.D. Student, Youssef Roman, PharmD, Ph.D.
Virginia Commonwealth University School of Pharmacy
➢ Genetic polymorphisms in drug-metabolizing enzymes have 
been linked to interindividual variabilities in the efficacy and 
toxicity of the most prescribed drugs. 
➢ Pharmacogenomics (PGx) provides a stronger scientific basis 
for optimizing drug therapy based on each patient’s genetic 
makeup.1
➢ The prevalence of  Single Nucleotide Polymorphisms (SNPs) 
in very important pharmacogenes (VIPs) in some  Asian 
subpopulations, Hawaiians, and Pacific Islanders are lacking. 
➢ The cytochrome P450 (CYP) 2C19 is a major hepatic enzyme 
and a member of the CYP family that metabolizes ~ 10% of 
commonly prescribed drugs.
➢ Clopidogrel is a prodrug, converted by CYP2C19 to its active 
metabolite, which is required for its anti-platelet activity.
➢ Multiple studies linked adverse cardiovascular outcomes 
(e.g., cardiovascular death, myocardial infarction, stroke, 
stent rethrombosis) to CYP2C19 genotype in clopidogrel-
treated ACS patients undergoing PCI.3-4,6
➢ Asian subgroups have substantially higher rates of being poor 
and intermediate CYP2C19 metabolizers, compared with 
Caucasians (allele frequencies: 29%-35% and 9%, and ~15% 
and 0.4%; respectively).5,7,8
OBJECTIVES
➢ To assess the prevalence of three CYP2C19 SNPs in 
post-partum women  self-reported of 100% Native 
Hawaiian (NT), Asian and Pacific Islander (PI) 
descent, compared with Europeans (EUR).
➢ To describe the clinical impact of CYP2C19 genetic 
polymorphisms on treating Asian, NT, and PI patients 
with clopidogrel, using the Clinical Pharmacogenetics 
Implementation Consortium (CPIC) guidelines.5
METHODS
➢ The Ensemble genome browser7,8 was used to estimate the 
frequencies of 3 major SNPs in EUR for CYP2C19, gene/SNP 
pairs included: CYP2C19 (rs12248560, rs4244285, and 
rs4986893).
➢ Data: De-identified DNA samples linked with limited clinical 
data procured from the University of Hawaii biospecimens’ 
repository9. 
➢ Chi-square or Fisher’s exact test was used, when appropriate, 
with P < 0.05 for significance to test the hypothesis that the 
genotype/allele frequencies between our study populations 
(i.e., Filipino, Japanese, Samoan, Korean, Marshallese, and 
Native Hawaiian differ from EUR.
➢ Quality control analysis: Genotypes that were not HWE (p < 






























































G/G 72.2 (363) 41.6 (79), (34.2, 
49.2)
45.1 (83), (37.5, 52.7) 48.1 (37), (37.7, 60.7) 58.2 (85), (50.7, 
66.9)
43.4 (53), (34.4, 
52.9)
42.5 (77), (35.4, 50.7)
G/A 26.6 (134) 45.2 (86), (37.9, 
52.9)
39.7 (73), (32.1, 47.3) 36.4 (28), (26, 50) 34.3 (50) (26.7, 43) 45.9 (56), (36.9, 
55.3)
44.8 (81), (37.6, 52.9)
A/A 1.2 (6) 13.2 (25), (5.7, 
20.8)
15.2 (28), (7.6, 22.8) 15.5 (12), (5.2, 28.2) 7.5 (11), (0, 16.2) 10.7 (13), (1.6, 
20.1)
12.7 (23), (5.5, 20.8)





G 85.5 (860) 64.2 (244), (59.5, 
69.3)
64.9 (239), (60.1, 70) 66.2 (102), (59.1, 
74.1)
75.3 (220), (70.5, 
80.3)
66.4 (162), (60.7, 
72.6)
64.9 (235), (60, 70.1)
A 14.5 (146) 35.8 (136), (31.1, 
40.9)
35.1 (129), (30.2, 40.1) 33.8 (52), (26.6, 41.6) 24.7 (72), (19.9, 
29.7)
33.6 (82), (27.9, 
39.8)
35.1 (127), (30.1, 
40.1)
P-value Reference <0.0001* <0.0001* <0.0001* 0.00004* <0.0001* <0.0001*
Figures 1 & 2: Bar plots of CYP2C19*2 G>A (rs4244285) 
Genotype and Allele Frequencies  
Characteristics                 n (%)













Table 1: Participants 
Characteristics
Table 2: CYP2C19*2, &*3 G>A (rs4244285) & (rs4986893), and CYP2C19*17 C>T (rs12248560)  Genotype/Allele 























































 G/G 100 (503) 82.9 (160), (78.2, 88.4) 82.3 (153), (77.4, 88) 84.8 (67), (78.5, 93) 95.3 (141), 
(92.6, 98.5)
80.3 (98), (73.8, 87.2) 83.2 (153), (78.3, 
88.5)
G/A 0 (0) 17.1 (33), (12.4, 22.6) 17.2 (32), (12.4, 
22.9)
13.9 (11), (14, 22.1) 4.7 (7), (2, 8) 19.7 (24), (13.1, 26.6) 15.8 (29), (10.9, 
21.2)
A/A 0 (0) 0 (0), (0, 5.5) 0.5 (1), (0, 6.2) 1.3 (1), (0, 9.4) 0 (0), (0, 3.3) 0 (0), (0, 6.9) 1.1 (2), (0, 6.5)




s G 100 (1006) 91.5 (353), (88.9, 94.1) 90.9 (338), (88.2, 
93.7)
91.8 (145), (88.1, 95.7) 97.6 (289), 
(96.3, 99.3)
90.2 (220), (86.9, 93.9) 91 (335), (88.3, 
93.8)
A 0 (0) 8.5 (33), (6, 11.2) 9.1 (34), (6.5, 12) 8.2 (13), (4.4, 12.2) 2.4 (7), (1, 4) 9.8 (24), (6.6, 13.5) 9 (33), (6.3, 11.7)
























































C/C 59.6 (300) 98.9 (186), 
(97.9, 1)
97.8 (181), (96.2, 
99.7)
97.4 (74), (94.7, 1) 89.2 (132), (85, 94.3) 97.8 (177), (96.1, 99.7)
C/T 36 (181) 1.1 (2), (0, 2.2) 2.2 (4) (0.5, 4) 2.6 (2), (0, 5.4) 10.1 (15), (6.1, 15.2) 2.2 (4), (0.6, 4.1)
T/T 4.4 (22) 0 (0), (0, 1.1) 0 (0) (0, 1.8) 0 (0), (0, 2.7) 0.7 (1), (0, 5.8) 0 (0), (0, 1.9)




s C 77.6 (781) 99.5 (374), 
(98.9, 1)
98.9 (366) (98.1, 
99.8)
98.7 (150), (97.4, 1) 94.3 (279), (91.9, 96.7) 98.9 (358), (98.1, 99.7)
T 22.4 (225) 0.5 (2), (0, 1.1) 1.1 (4) (0.3, 2) 1.3 (2), (0, 2.7) 5.7 (17), (3.4, 8.2) 1.1 (4), (0, 1.9)
P-value Reference <0.0001* <0.0001* <0.0001* <0.0001* <0.0001*
Figures 3 & 4: Bar plots of CYP2C19 *3 G>A (rs4986893), 
Genotype and Allele Frequencies  
Figure 7: Algorithm to assist guiding the selection of the most 
appropriate treatment plan for patients in the population of interest 
using Clinical Pharmacogenetics Implementation Consortium (CPIC)5
guidelines.
Figure-3 Figure-4





➢ This was a retrospective data analysis of a study that used 
targeted sequencing; hence we were limited by the variants 
assayed.
➢ Race of participants was self-reported.
➢ Participants were post-partum women only.
➢ Significant differences in genotype and allele frequencies of 
variants in CYP2C19 were found between 
Asians/Hawaiians/Pacific Islanders and Europeans. 
➢ CYP2C19 *2 and *3 variants were detected at higher 
frequencies in Asians, Hawaiians, and Pacific Islanders, 
compared with Europeans. 
➢ Knowledge of individual’s CYP2C19 metabolizer status may 
be useful in prescribing clopidogrel in our studied populations. 
➢ Our results are consistent with published reports of Asian 
populations being enriched with the reduced or loss of 
function alleles of CYP2C19 compared with Europeans.
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